Betta Pharmaceuticals Co., Ltd.
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Betta Pharmaceuticals Co., Ltd.
Asia Deal Watch: Taiho Brings Cullinan Pearl Back In House
Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.
Agenus PD-1 Down But Not Out With Cervical Cancer BLA Withdrawal
The company announced it would withdraw the BLA for balstilimab monotherapy in cervical cancer following Keytruda’s full approval, but it plans to keep developing the drug.
Finance Watch: Big Bucks For T-regs In Autoimmune Diseases, Inflammation
GentiBio closed a $157m series A venture capital round, while clinical trial innovator Reify Health raised a $220m series C and Neurelis secured $150m. Also, IPOs slowed in August, but Adagio and Eliem grossed $309.4m and $80m, respectively, and RNA firm Greenlight will go public in a $282m SPAC deal.
Oncology, Cell Therapy Developers Bag $175m In China
Investors continue to focus on anticancer therapies including small molecule drugs and cell therapies in China.